Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single‐center experience

Abstract excerpt

Juvenile scleroderma (JS) is a group of diseases characterized by increased skin thickness and fibrosis. It is the third-most common rheumatic condition in childhood. There are two major forms of the disease: juvenile localized scleroderma (JLS) and juvenile systemic sclerosis (JSSc), both classified into different subtypes depending on the extent of the disease and the depth of the lesions.1 JLS, also known as...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dupuytren's Contracture and Treatments
• Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
• Share to Systemic Sclerosis and Related Diseases